Webcast Alert: NexMed, Inc. Announces Its InformedInvestors.com Presentation Webcast.EAST WINDSOR East Windsor is the name of the following places in the United States of America:
in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : NEXM) announces the following Webcast: What: NexMed, Inc. InformedInvestors.com Presentation Webcast When: August 24, 2006 @ 01:30 PM Eastern Where: http://www.investorcalendar.com/EventPage.asp?ID=108073 How: Live over the Internet -- Simply log on to the web at the address above. Contact: Deborah Carty, (609) 371-8123 x159 If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=108073 or http://www.investorcalendar.com/ NexMed, Inc., founded in 1987 and based in East Windsor, NJ, is an emerging specialty pharmaceutical and drug delivery technology company currently developing innovative pharmaceutical products based on its NexACT(R) transdermal drug delivery platform technology. NexACT(R) enables drugs to be better absorbed through the skin. This may provide a highly effective topical approach to diseases currently being treated by systemic (oral or injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. ) therapies. Drugs delivered topically with NexACT(R) are expected to improve therapeutic outcomes and reduce or eliminate systemic side effects Side effects Effects of a proposed project on other parts of the firm. that often accompany oral or injectable medications. NexMed's lead product is Alprox-TD(R), which has completed two pivotal Phase 3 studies. Alprox-TD(R) is a topical formulation that incorporates alprostadil, a vasodilator vasodilator /vaso·di·la·tor/ (-di-la´ter) 1. causing dilatation of blood vessels. 2. a nerve or agent that does this. va·so·di·la·tor n. , with the NexACT(R) delivery technology for the treatment of male Erectile Dysfunction Erectile Dysfunction Definition Erectile dysfunction (ED), formerly known as impotence, is the inability to achieve or maintain an erection long enough to engage in sexual intercourse. . The Company is also developing Femprox(R), a topical formulation that incorporates alprostadil with the NexACT(TM) technology for the treatment of Female Sexual Arousal Disorder Female Sexual Arousal Disorder Definition Female sexual arousal disorder (FSAD) occurs when a woman is continually unable to attain or maintain arousal and lubrication during intercourse, is unable to reach orgasm, or has no desire for sexual . In September 2005, NexMed entered into an exclusive, global licensing agreement with Novartis International Pharmaceutical Ltd., for its proprietary NM100060 nail lacquer lacquer, solution of film-forming materials, natural or synthetic, usually applied as an ornamental or protective coating. Quick-drying synthetic lacquers are used to coat automobiles, furniture, textiles, paper, and metalware. treatment for onychomycosis, commonly known as nail fungus. It is anticipated that Novartis will initiate a Phase 3 study during the second half of 2006. Under the terms of the agreement, NexMed will receive up to $51 million, including upfront and milestone payments based on the achievement of specific development and regulatory milestones. Additionally, NexMed will receive royalties on product sales that could reach double digits as sales escalate. NexMed's strategy includes pursuing partnerships with other pharmaceutical companies regarding the incorporation of its NexACT(R) technology with established brands, with the goal of extending product patent life while enhancing efficacy and patient compliance. |
|
||||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion